Squarepoint
CMPX icon

Squarepoint’s Compass Therapeutics CMPX Stock Holding History

Squarepoint’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$266K Sell
50,202
-75,990
-60% -$439K ﹤0.01% 3800
2025
Q4 		$678K Buy
126,192
+38,339
+44% +$177K ﹤0.01% 2950
2025
Q3 		$307K Buy
87,853
+67,080
+323% +$212K ﹤0.01% 3645
2025
Q2 		$54K Buy
+20,773
New +$42.8K ﹤0.01% 4291
2025
Q1 		– Sell
-24,072
Closed -$34.9K – 4688
2024
Q4 		$34.9K Buy
+24,072
New +$40K ﹤0.01% 4898
2024
Q3 		– Sell
-64,133
Closed -$64.1K – 4173
2024
Q2 		$64.1K Buy
64,133
+13,321
+26% +$19.5K ﹤0.01% 3875
2024
Q1 		$101K Sell
50,812
-37,908
-43% -$65.5K ﹤0.01% 3798
2023
Q4 		$138K Buy
+88,720
New +$154K ﹤0.01% 3695
2023
Q2 		– Sell
-16,263
Closed -$53.2K – 3618
2023
Q1 		$53.2K Buy
+16,263
New +$63.9K ﹤0.01% 3047

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Squarepoint's CMPX Position: Q1 2026 in Review

Squarepoint reduced its Compass Therapeutics (CMPX) stake by 60% in Q1 2026, selling an estimated $439K and leaving 50,202 shares worth $266K. The position accounts for ﹤0.01% of the portfolio, ranked #3800.

Squarepoint first reported a position in CMPX in Q1 2023 and has held it in 9 quarters since. The position peaked at $678K in Q4 2025. 201 funds tracked by Wall St. Rank hold CMPX as of Q1 2026.

  • Squarepoint held 50,202 shares of Compass Therapeutics worth $266K as of Q1 2026.
  • Squarepoint sold 75,990 Compass Therapeutics shares in Q1 2026, an estimated $439K.
  • Compass Therapeutics made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #3800 holding.
  • Squarepoint first reported a position in Compass Therapeutics in Q1 2023 and has held it in 9 quarters since.
  • Squarepoint's Compass Therapeutics position peaked at $678K in Q4 2025.
  • 201 funds tracked by Wall St. Rank held Compass Therapeutics as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.